NANTONG CITY, China, Sept. 30 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) (“Sinobiopharma” or, the “Company”) is pleased to announce that it has appointed Mr. Xinjie (James) Mu as the new Chief Financial Officer and as a director on the Board. Dr. Lequn Huang resigned as the Chief Financial Officer in order to make room for the appointment of Mr. Mu.
Mr. Mu has more than twelve years experience in the financial field. Most recently, Mr. Mu has been an independent consultant working for China based US public companies. Prior to that, he was a Chief Financial Officer at Jingwei International Limited (OTCBB: JNGW.OB). Prior to that, he served as a senior accountant at Geller and Company in New York City. Mr. Mu is also a Director of China Infrastructure Investment Corporation (NASDAQ: CIIC) since March 2008. Fluent in Mandarin and English, Mr. Mu holds a Bachelor of Science degree from Hebei University of Science and Technology, and a Master of Business Administration from Baruch College at the City University of New York.
“We are greatly pleased to have Mr. Mu join the Company and we are sure that his professional background and strong management skills will add tremendous value to Sinobiopharma’s future endeavors,” stated Dr. Lequan Huang, President and CEO of Sinobiopharma.
Separately, the Company announces that Mr. Martin Shen resigned as director of the Board for personal reasons.
“On behalf of the Board of Directors and Sinobiopharma, I want to personally thank Mr. Shen for his contributions to the Company and wish him well,” said Dr. Lequn Huang, President and CEO of Sinobiopharma.
About Sinobiopharma
Sinobiopharma Inc. is a fully integrated and highly innovative biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world’s fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company’s current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.
FORWARD LOOKING STATEMENTS
This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
